NanoString Technologies Management

Management criteria checks 2/4

NanoString Technologies' CEO is Brad Gray, appointed in Jun 2010, has a tenure of 13.83 years. total yearly compensation is $7.60M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €132.75K. The average tenure of the management team and the board of directors is 7.6 years and 7.6 years respectively.

Key information

Brad Gray

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage	8.5%
CEO tenure	13.8yrs
CEO ownership	1.0%
Management average tenure	7.6yrs
Board average tenure	7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brad Gray's remuneration changed compared to NanoString Technologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$166m
Jun 30 2023	n/a	n/a	-US$166m
Mar 31 2023	n/a	n/a	-US$161m
Dec 31 2022	US$8m	US$645k	-US$160m
Sep 30 2022	n/a	n/a	-US$145m
Jun 30 2022	n/a	n/a	-US$139m
Mar 31 2022	n/a	n/a	-US$127m
Dec 31 2021	US$6m	US$640k	-US$115m
Sep 30 2021	n/a	n/a	-US$109m
Jun 30 2021	n/a	n/a	-US$99m
Mar 31 2021	n/a	n/a	-US$99m
Dec 31 2020	US$5m	US$638k	-US$110m
Sep 30 2020	n/a	n/a	-US$63m
Jun 30 2020	n/a	n/a	-US$65m
Mar 31 2020	n/a	n/a	-US$57m
Dec 31 2019	US$7m	US$569k	-US$41m
Sep 30 2019	n/a	n/a	-US$86m
Jun 30 2019	n/a	n/a	-US$80m
Mar 31 2019	n/a	n/a	-US$80m
Dec 31 2018	US$3m	US$565k	-US$77m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$60m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$2m	US$562k	-US$44m

Compensation vs Market: Brad's total compensation ($USD7.60M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.

CEO

Brad Gray (46 yo)

13.8yrs

Tenure

US$7,596,268

Compensation

Mr. R. Bradley Gray, also known as Brad, has been the Chief Executive Officer and President of NanoString Technologies, Inc. since June 29, 2010. Mr. Gray worked at Genzyme Genetics, the diagnostic service...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
R. Gray	CEO, President & Director	13.8yrs	US$7.60m	1.02% $ 132.7k
K. Bailey	Chief Financial Officer	6.3yrs	US$2.32m	0.25% $ 32.8k
Joseph Beechem	Chief Scientific Officer and Senior VP of Research & Development	12yrs	US$2.32m	0.29% $ 38.1k
Mark Winham	Senior Vice President of Operations	4.5yrs	no data	no data
Douglas Farrell	Vice President of Investor Relations & Corporate Communications	7.6yrs	no data	no data
Kathryn Surace-Smith	Senior VP of Human Resources & Legal Affairs and Corporate Secretary	11.2yrs	no data	no data
Elizabeth Schneider	Senior Global Marketing Manager	no data	no data	no data
Philippa Webster	Senior Principal Scientist	no data	no data	no data
Todd Garland	Chief Commercial Officer	less than a year	no data	no data
Praveer Sharma	Field Application Scientist	no data	no data	no data
Anne van der Valk	Executive	no data	no data	no data

7.6yrs

Average Tenure

54yo

Average Age

Experienced Management: 0F1's management team is seasoned and experienced (7.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
R. Gray	CEO, President & Director	13.8yrs	US$7.60m	1.02% $ 132.7k
William Young	Independent Director	14.3yrs	US$276.36k	0.13% $ 16.6k
Elisha Finney	Independent Chairman	6.9yrs	US$243.86k	0.045% $ 5.8k
Charles Waite	Independent Director	19.8yrs	US$243.86k	0.079% $ 10.3k
Janet George	Independent Director	3.1yrs	US$233.86k	0.044% $ 5.7k
Kirk Malloy	Independent Director	7.6yrs	US$231.36k	0.050% $ 6.6k
Teresa Foy	Independent Director	2yrs	US$306.44k	0.021% $ 2.7k
Gregory Norden	Independent Director	11.8yrs	US$238.86k	0.099% $ 12.8k
Dana Rollison	Independent Director	3.1yrs	US$228.86k	0.044% $ 5.7k
Chad Nusbaum	Member of Sequencing Advisory Board	no data	no data	no data

7.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 0F1's board of directors are considered experienced (7.6 years average tenure).

NanoString Technologies Management

Management criteria checks 2/4

Key information

Recent management updates

Nanostring Appoints Todd Garland as Chief Commercial Officer

Independent Director recently bought €187k worth of stock

Independent Director recently bought €116k worth of stock

CEO, President & Director recently bought €469k worth of stock

NanoString Technologies, Inc. Announces Resignation of Robert Hershberg from the Board

Chief Financial Officer recently sold €154k worth of stock

Recent updates

The Nasdaq Stock Market to Delist the Common Stock of Nanostring Technologies

NanoString Technologies, Inc. announced delayed annual 10-K filing

NanoString Technologies, Inc. announced delayed annual 10-K filing

Patient Square Capital, LP agreed to acquire Substantially all assets of global business operations from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $220 million.

Patient Square Capital, LP agreed to acquire Substantially all assets of global business operations from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $220 million.

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from NASDAQ Composite Index

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from S&P Global BMI Index

Motion for Joint Administration Approved for NanoString Technologies, Inc.

Motion for Joint Administration Filed by NanoString Technologies, Inc.

NanoString Technologies, Inc. Filed for Bankruptcy

Nanostring Launches the CosMx 6,000 Plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

NanoString Technologies, Inc. Releases the First Public Dataset of the Whole Transcriptome Obtained At True Single-Cell Resolution on the CosMx Spatial Molecular Imager

NanoString Technologies Receives Non-Compliance Notice from Nasdaq

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.78 loss per share (vs US$0.79 loss in 3Q 2022)

NanoString Technologies, Inc. to Report Q3, 2023 Results on Nov 06, 2023

NanoString Technologies, Inc. Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

Nanostring Appoints Todd Garland as Chief Commercial Officer

New major risk - Negative shareholders equity

NanoString Technologies, Inc. Reiterates Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.84 loss in 2Q 2022)

Delaware District Court Permits NanoString Technologies, Inc.'s Counterclaims That 10x Genomics and Harvard Violated the Antitrust Laws

NanoString Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

10X Genomics, Inc. Files New Patent Litigation Against Nanostring Technologies, Inc. and Vizgen, Inc. in the European Unified Patent Court

Independent Director recently bought €187k worth of stock

10X Genomics Wins Permanent Injunction Against Nanostring's CosMX Products

First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.86 loss in 1Q 2022)

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Independent Director recently bought €116k worth of stock

Full year 2022 earnings released: US$3.44 loss per share (vs US$2.54 loss in FY 2021)

NanoString Technologies, Inc. to Report Q4, 2022 Results on Feb 28, 2023

NanoString Technologies, Inc. Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

NanoString Technologies, Inc. Provides Product and Service Revenue Guidance for the Fourth Quarter and Full Year 2022

CEO, President & Director recently bought €469k worth of stock

NanoString Technologies, Inc Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform

Third quarter 2022 earnings released: US$0.79 loss per share (vs US$0.69 loss in 3Q 2021)

NanoString Technologies, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Nanostring Technologies, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$0.60 loss in 2Q 2021)

NanoString Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022

NanoString Unveils AtoMx Spatial Informatics Portal at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

Nanostring Technologies, Inc. Announces Plans to Commercially Unveil the Cosmx™ Spatial Molecular Imager

NanoString Technologies, Inc. Launches Integrated Informatics to Facilitate Spatial Biology Research Using Next Generation Sequencing

First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.62 loss in 1Q 2021)

NanoString Technologies, Inc. Announces Resignation of Robert Hershberg from the Board

NanoString Technologies, Inc. Launches New nCounter Pro Analysis System

Chief Financial Officer recently sold €154k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NanoString Technologies, Inc. Announces Release of a Fully Automated GeoMx RNA Protocol on BOND RX Research Staining Systems

NanoString Technologies, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Nanostring Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.56 loss in 3Q 2020)

Insider recently sold €1.2m worth of stock

Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.72 loss in 2Q 2020)

Nanostring Technologies, Inc. Announces the Launch of the Ncounter Stem Cell Characterization Panel for the Analysis and Optimization of Stem Cell Lines

NanoString's GeoMx Mouse Whole Transcriptome Atlas Expands Leadership in Spatial Genomics by Enabling Genome-Wide RNA Profiling

First quarter 2021 earnings released: US$0.62 loss per share (vs US$1.04 loss in 1Q 2020)

NanoString Technologies, Inc. Provides Revenue Guidance for the Second Quarter 2021

NanoString Technologies, Inc. Announces Board Appointments

Nanostring Appoints Dr. Dana Rollison and Janet George to Board of Directors

NanoString Launches Technology Access Program for the Spatial Molecular Imager (SMI) Platform

Revenue beats expectations

Full year 2020 earnings released: US$2.82 loss per share (vs US$1.18 loss in FY 2019)

NanoString Technologies, Inc. Announces the Commercial Availability of the Whole Transcriptome Atlas

New 90-day high: €68.50

Nanostring Technologies, Inc. Announces the Publication of Study in the Journal Nature Medicine Thatused Nanostring’S Geomx Digital Spatial Profiler and the New Whole Transcriptome Atlas to Profile Sarcoma Tissue

New 90-day high: €61.00